Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase

ACS Medicinal Chemistry Letters

Volumn 6, Issue 8, 2015, Pages 840-844

  Zigmond, Ehud ^a   Ya'acov, Ami Ben ^a   Lee, Hyunbeom ^b   Lichtenstein, Yoav ^a   Shalev, Zvi ^a   Smith, Yoav ^a   Zolotarov, Lidya ^a   Ziv, Ehud ^a   Kalman, Rony ^a   Le, Hoang V ^b   Lu, Hejun ^b   Silverman, Richard B ^b   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

alpha fetoprotein; antitumor agent; GABA aminotransferase; Hepatocellular carcinoma; ornithine aminotransferase; selective inhibitors

Indexed keywords

3 AMINO 4 (HEXAFLUOROPROPAN 2 YLIDENE)CYCLOPENTANE 1 CARBOXYLIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GABACULINE; ORNITHINE OXOACID AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA MICROARRAY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; GENE OVEREXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ORNITHINE AMINOTRANSFERASE GENE; PRIORITY JOURNAL; PROTEIN SECRETION; PSAMMOMYS OBESUS; TUMOR GENE;

MUS; PSAMMOMYS OBESUS;

EID: 84938906694     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00153     Document Type: Article

References (45)

1. Sherman, M.; Bruix, J.; Porayko, M.; Tran, T.; Committee, A. P. G. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations Hepatology 2012, 56, 793
2. Tan, C. H.; Low, S. C.; Thng, C. H. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review Int. J. Hepatol 2011, 2011, 519783
3. Yang, J. D.; Roberts, L. R. Hepatocellular carcinoma: a global view Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 448
4. Cho, Y. K.; Kim, J. K.; Kim, M. Y.; Rhim, H.; Han, J. K. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies Hepatology 2009, 49, 453
5. Breuhahn, K.; Gores, G.; Schirmacher, P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches Hepatology 2011, 53, 2112
6. Llovet, J. M.; Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival Hepatology 2003, 37, 429
7. de Lope, C. R.; Tremosini, S.; Forner, A.; Reig, M.; Bruix, J. Management of HCC J. Hepatol. 2012, 56 (Suppl 1) S75
8. Xie, B.; Wang, D. H.; Spechler, S. J. Sorafenib for treatment of hepatocellular carcinoma: a systematic review Dig. Dis. Sci. 2012, 57, 1122
9. Brosnan, M. E.; Brosnan, J. T. Hepatic glutamate metabolism: a tale of 2 hepatocytes Am. J. Clin. Nutr. 2009, 90, 857S
10. Cadoret, A.; Ovejero, C.; Terris, B.; Souil, E.; Levy, L.; Lamers, W. H.; Kitajewski, J.; Kahn, A.; Perret, C. New targets of beta-catenin signaling in the liver are involved in the glutamine targets of beta-catenin signaling in the liver are involved in the glutamine metabolism Oncogene 2002, 21, 8293
11. Lim, K. T.; Gupta, M. K.; Lee, S. H.; Jung, Y. H.; Han, D. W.; Lee, H. T. Possible involvement of Wnt/beta-catenin signaling pathyway in hatching and trophectoderm differentiation of pig blastocysts Theriogenology 2013, 79, 284
12. Gupta, A.; Verma, A.; Mishra, A. K.; Wadhwa, G.; Sharma, S. K.; Jain, C. K. The Wnt pathway: emerging anticancer strategies Recent Pat. Endocr. Metab. Immune Drug Discovery 2013, 7, 138
13. Voronkov, A.; Krauss, S. Wnt/beta-catenin signaling and small molecule inhibitors Curr. Pharm. Des. 2013, 19, 634
14. Lucero, O. M.; Dawson, D. W.; Moon, R. T.; Chien, A. J. A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanom and other cancers Curr. Oncol Rep. 2010, 12, 314
15. White, B. D.; Chien, A. J.; Dawson, D. W. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers Gastroenterology 2012, 142, 219
16. Colnot, S.; Decaens, T.; Niwa-Kawakita, M.; Godard, C.; Hamard, G.; Kahn, A.; Giovannini, M.; Perret, C. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellulcar carcinomas Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 17216
17. Colnot, S.; Niwa-Kawakita, M.; Hamard, G.; Godard, C.; Le Plenier, S.; Houbron, C.; Romagnolo, B.; Berrebi, D.; Giovannini, M.; Perret, C. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers Lab Invest. 2004, 84, 1619
18. Zucman-Rossi, J.; Laurent-Puig, P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies Pharmacogenomics 2007, 8, 997
19. Zucman-Rossi, J.; Benhamouche, S.; Godard, C.; Boyault, S.; Grimber, G.; Balabaud, C.; Cunha, A. S.; Bioulac-Sage, P.; Perret, C. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas Oncogene 2007, 26, 774
20. Thompson, M. D.; Monga, S. P. WNT/beta-catenin signaling in liver health and disease Hepatology 2007, 45, 1298
21. Nejak-Bowen, K. N.; Monga, S. P. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad Semin. Cancer Biol. 2011, 21, 44
22. Dahmani, R.; Just, P. A.; Perret, C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma Clin. Res. Hepatol. Gastroenterol. 2011, 35, 709
23. Armengol, C.; Cairo, S.; Fabre, M.; Buendia, M. A. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model Int. J. Biochem. Cell Biol. 2011, 43, 265
24. Amadasi, A.; Bertoldi, M.; Contestabile, R.; Bettati, S.; Cellini, B.; di Salvo, M. L.; Borri-Voltattorni, C.; Bossa, F.; Mozzarelli, A. Pyridoxal 5′-phosphate enzymes as targets for therapeutic agents Curr. Med. Chem. 2007, 14, 1291
25. Souba, W. W. Glutamine and cancer Ann. Surg. 1993, 218, 715
26. Medina, M. A. Glutamine and cancer J. Nutr. 2001, 131, 2539S
27. Wise, D. R.; Thompson, C. B. Glutamine addiction: A new therapeutic target in cancer Trends Biochem. Sci. 2010, 35, 427
28. Dang, C. V. Links between metabolism and cancer Genes Dev. 2012, 26, 877
29. DeBerardinis, R. J.; Cheng, T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer Oncogene 2010, 29, 313
30. Shanware, N. P.; Mullen, A. R.; DeBerardinis, R. J.; Abraham, R. T. Glutamine: pleiotropic roles in tumor growth and stress resistance J. Mol. Med. 2011, 89, 229
31. DeBerardinis, R. J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C. B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 19345
32. Miyasaka, Y.; Enomoto, N.; Nagayama, K. Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization Br. J. Cancer 2001, 85, 228
33. Kobayashi, K.; Morris, H. P.; Katunuma, N. Studies on the turnover rates of ornithine aminotransferase in Morris hepatoma 44 and host liver J. Biochem 1976, 80, 1085
34. Rosenau, J.; Hooman, N.; Rifai, K. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplanation for hepatitis B-relatede disease: failure of humoral and cellular immune response Transpl In. 2006, 19, 828
35. Kaiser, N.; Cerasi, E.; Leibowitz, G. Diet-induced diabetes in the sand rat (Psammomys obesus) Methods Mol. Biol. 2012, 933, 89
36. Ungar, H.; Adler, J. H. The histogenesis of hepatoma occurring spontaneously in a strain of sand rats (Psammomys obesus) Am. J. Pathol. 1978, 90, 399
37. Shah, S. A.; Shen, B. W.; Brunger, A. T. Human ornithine aminotransferase complexed with L-canaline and gabculine: structural basis for substrate recognition Structure 1997, 5, 1067
38. Palfreyman, M. G.; Schechter, P. J.; Buckett, W. R.; Tell, G.; Koch-Weser, J. The pharmacology of GABA-transaminase inhibitors Biochem. Pharamacol. 1981, 30, 817
39. Soper, T. S.; Manning, J. M. Inactivation of pyridoxal phosphate enzymes by gabaculine. Correlation with enzymic exchange of beta-protons J. Biol. Chem. 1982, 257, 13930
40. Wood, J. D.; Kurylo, E.; Tsui, D. Inhibition of aminotransferase enzyme systems by gabaculine Neurosci. Lett. 1979, 14, 327
41. Rando, R. R. Mechanism of the irreversible inhibition of gamma-aminobutyric acid-alpha-ketoglutaric acid transaminase by the neutrotoxin gabaculine Biochemistry 1977, 16, 4604
42. Fu, M.; Silverman, R. B. Isolation and characterization of the product of inactivation of gamma-aminobutyric acid aminotransferase by gabaculine Bioorg. Med. Chem. 1999, 7, 1581
43. Lee, H.; Juncosa, J. I.; Silverman, R. B. Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs Med. Res. Rev. 2015, 35, 286-305
44. Silverman, R. B. The 2011 E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances: (1S,3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms J. Med. Chem. 2012, 55, 567
45. Lu, H.; Silverman, R. B. Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitors J. Med. Chem. 2006, 49, 7404